Table 4. Risks of outcomes in the subgroups of immunocompromised COVID-19 patients after IPTW.
| Outcomes | Malignancy (n = 3,343) | Use of corticosteroids (n = 1,754) | Use of immunosuppressants (n = 433) | ≥2 causes (n = 444) | ||||
|---|---|---|---|---|---|---|---|---|
| Adjusted OR* | p-value | Adjusted OR | p-value | Adjusted OR | p-value | Adjusted OR | p-value | |
| (95% CI) | (95% CI) | (95% CI) | (95% CI) | |||||
| In-hospital mortality | 1.24 | 0.153 | 3.36 | < .001 | 1.19 | 0.495 | 2.79 | < .001 |
| (0.92–1.66) | (2.48–4.54) | (0.73–1.93) | (1.80–4.34) | |||||
| Conventional oxygen therapy | 1.02 | 0.829 | 1.47 | < .001 | 0.08 | 0.027 | 2.10 | < .001 |
| (0.88–1.18) | (1.25–1.72) | (0.01–0.75) | (1.61–2.74) | |||||
| High flow nasal cannula | 1.42 | 0.210 | 1.12 | 0.513 | 1.09 | 0.557 | 1.71 | 0.020 |
| (1.35–1.49) | (0.80–1.58) | (0.82–1.46) | (1.09–2.68) | |||||
| Mechanical ventilation | 1.25 | 0.043 | 0.17 | < .001 | 1.26 | 0.331 | 1.01 | 0.986 |
| (1.17–1.34) | (0.07–0.40) | (0.79–2.03) | (0.47–2.17) | |||||
| ECMO | NA | NA | 0.78 | 0.504 | NA | |||
| (0.37–1.64) | ||||||||
| Vasopressor use | 1.23 | 0.179 | 1.21 | 0.294 | NA | 0.966 | 2.78 | < .001 |
| (0.91–1.67) | (0.85–1.73) | (1.74–4.43) | ||||||
| Renal replacement therapy | 1.51 | 0.053 | NA | 0.70 | 0.220 | 1.85 | 0.017 | |
| (1.33–1.72) | (0.40–1.23) | (1.50–2.27) | ||||||
| Acute heart failure | 1.45 | < .001 | 1.28 | 0.029 | 0.34 | 0.003 | 1.30 | 0.182 |
| (1.21–1.75) | (1.03–1.59) | (0.17–0.69) | (0.88–1.92) | |||||
IPTW: Inverse probability of treatment weighting; OR: Odds ratio; CI: Confidence interval; ECMO: Extracorporeal membrane oxygenation; NA: Not applicable.
* Adjusted for Charlson comorbidity index, age, and region.